Although, NSC-23766 was initially published as specific for Rac1, it has meanwhile been shown by different groups that NSC-23766 also targets Rac2, at least in p210-BCR-ABL+ HSPCs/CML cells [61,96]. Here, EVPL is linked to chronic myelogenous leukemia, BCR-ABL1 positive.